Ammonia filtration key to efficient antibiotics production
Leading antibiotics manufacturer reduces unacceptable levels of production downtime.
Amazon Filters has installed a combination SupaPore FPW/SupaPore VPBA filtration system at a leading antibiotics manufacturer’s fermentation plant enabling them to reduce production downtime resulting in significant cost savings.
Efficient antibiotic production requires the use of high-quality ammonia to adjust the pH of the fermentation process. Yet, the antibiotics manufacturer was receiving batches of ammonia of varying quality, which required sterile filtering before use. Despite this precaution, the manufacturer was having to replace blocked final membrane filters on a daily basis resulting in unacceptable levels of production downtime and the high costs of replacement filters.
After studying the production process, Amazon Filters recommended using a SupaPore FPW pre-filter to protect the final membrane filter the SupaPore VPBA replacing the customer’s existing final filter, with a micron rating of 0.2um. This membrane filter is specifically designed to meet the demands of pharmaceutical producers requiring efficient and reliable microbiological sterilisation and bioburden control - essential factors in antibiotic production.
Upon installation of the new filters, the customer saw immediate benefits. They are experiencing up to 300% longer life of the final membrane filter, making the filtration system much more cost effective. In addition, Amazon Filters has added value to the process by offering local and readily available support ,which is vital on such a critical system.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.